In the world of investments, certain companies stand out as ideal choices for long-term portfolios. These businesses not only lead in their respective markets but also demonstrate consistent earnings growth and promising future prospects. This article highlights two healthcare giants that are perfect for investors looking to buy now and hold onto for the next five to ten years. Both companies offer unique advantages that make them excellent additions to any portfolio.

The Robotic Surgery Pioneer with a Strong Market Presence

This section delves into a company that has revolutionized surgical procedures through advanced technology. The firm's flagship product is a versatile system used across multiple medical specialties, from cardiac surgeries to general procedures. Despite initial challenges during the pandemic, the company has rebounded strongly, showing impressive year-over-year growth in both procedure volumes and revenue. The installed base of its primary system has expanded significantly, indicating strong market adoption.

The company's competitive advantage stems from two key factors: surgeon training and hospital investment. Surgeons familiar with the platform are unlikely to switch to competitors, while hospitals aim to maximize their return on the substantial investment made in these systems. Additionally, the majority of the company's revenue comes from recurring sales of instruments and accessories, ensuring steady income streams beyond the initial sale of the robotic systems. Although the stock may appear pricey at first glance, its leadership position, robust moat, and reliable recurrent revenue justify the valuation.

A Diversified Healthcare Leader with Steady Growth

This segment explores a healthcare conglomerate with a broad range of products and services spanning four distinct sectors. This diversification provides stability, allowing the company to maintain overall growth even when one division faces challenges. For instance, while the diagnostics sector has seen a decline due to reduced coronavirus testing, other units have thrived, contributing to an overall revenue increase. The company's history of delivering consistent gains in revenue and profit further solidifies its appeal.

Among its market-leading products are nutritional brands and innovative medical devices, including a continuous glucose monitoring system that generated significant revenue growth. The company continues to innovate, launching new platforms like a wellness-focused glucose monitoring system that doesn't require a prescription. Trading at a reasonable multiple, this diversified healthcare leader offers a compelling value proposition for long-term investors seeking stable growth and a proven track record of success.